Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Next Previous
Trial Profile

A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 05 Jul 2024 Numbers of arms changed from 1 to 2. Experimental: SHR-A1811 arm added to study protocol. Interventional Study Model changed from Single Group Assignment to Parallel Assignment. Allocation changed to Non-Randomized. Planned number of patients also increased.
  • 05 Jul 2024 Planned number of patients changed from 61 to 65.
  • 05 Jul 2024 Planned End Date changed from 28 Feb 2029 to 28 Feb 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top